Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial

Affiliations

• ¹ Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
• ² University of Washington Heart Institute, Seattle, Washington, USA.
• ³ Interdisciplinary Research Center 'Health Science', Sant'Anna School of Advanced Studies, Pisa, Italy.
• ⁴ National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
• ⁵ Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
• ⁶ AdventHealth Translational Research Institute, Orlando, Florida, USA.
• ⁷ Velocity Clinical Research, Medical City Dallas, Dallas, Texas, USA.
• ⁸ School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.